Podcast with MedAsian

GA evolved from back-office compliance to a strategic driver of healthcare valuation, shaping market confidence in future revenue. Valuation hinges on the probability of future cash flows, heavily impacted by regulatory, reimbursement, and adoption uncertainties—not just science. Framework “What, How Much, Who”: timing of approval, reimbursement/pricing level, and real-world clinical adoption at s...

Section 1260H & WuXi AppTec 1260H is a policy signaling tool, not a sanction – identifies companies linked to China's military-civil fusion Creates indirect but real consequences: investor scrutiny, partner caution, ESG risk perception WuXi AppTec (listed) vs. WuXi Biologics (not): difference = value chain position. AppTec sits upstream (discovery, data, genomics) → more sensitive. Biolog...

Evolution of globalization: Chinese healthcare companies have moved from transactional exports and licensing to becoming globally integrated players—pursuing co-development, overseas manufacturing, acquisitions, and ecosystem partnerships. Licensing surge: Driven by higher-quality Chinese innovation (e.g., ADCs, oncology) and MNCs’ need to fill pipelines. Licensing validates technology and provide...

The Trump visit tested the political will to stabilize U.S.-China relations and prevent uncontrolled escalation amid deep strategic competition, supply chain restructuring, and technology restrictions. Rather than a full reset, it signaled a shift toward more managed competition, with both sides prioritizing communication, strategic predictability, and reduced economic disruption. Key business sig...

National strategy: China has elevated AI healthcare into a broader national agenda, linking it to economic modernization, tech leadership, and solving structural pressures like an aging population and uneven medical access. Multi-agency governance: Regulation involves the National Health Commission (clinical integration), NMPA (device approvals), and Cyberspace Administration (data and algorithms)...

Surge drivers: Advances in deep learning and large language models, mounting pressure from aging populations and rising costs, plus heavy investment and government backing are converging to make AI a practical, system-shaping force in healthcare. Market size: The global AI healthcare market could approach $190 billion by 2030, with China’s medical large-model segment alone surpassing RMB 100 billi...

For multinational pharma in China: A strategic trade-off emerges between US market access and global efficiency. High tariffs penalize offshore production, pushing firms from “China for Global” to “China for China” models. Expect more US-based manufacturing, fragmented supply chains, and pricing pressures (e.g., MFN agreements). For Chinese pharma companies: Diversify exports beyond the US (Europe...

What is Section 232? A U.S. trade law allowing the President to restrict imports deemed a threat to "national security." It is now being applied to pharmaceuticals, reframing medicine as a strategic asset rather than just a commercial good. Why Now? The shift is driven by three converging factors: supply chain vulnerability exposed by recent crises, intensifying geopolitical competition...

A quick summary of this episode. US-China relations : Managed competition with selective decoupling, not full decoupling. Upcoming Trump visit expected to be transactional, not a dramatic reset. Bilateral investment : Investment is increasingly political. Success depends on aligning with local US priorities (job creation, manufacturing, clean energy, healthcare). Most viable locations: Midwest and...

In this MedAsian podcast episode, Director of Government Affairs Felix Li shares insights from a two-week trip to Washington, D.C., outlining the evolving US-China landscape and what it means for multinational businesses. Selective Decoupling: US-China relations are defined by "managed competition" under deep interdependence—neither full decoupling nor full normalization, but a strategic...

The quick summary of this episode of Podcast with MedAsian. New 5-Year Plan & Shift to Quality: 2026 marks the start of China’s 15th Five-Year Plan, with a moderate 4.5–5% GDP target that prioritizes quality over speed . The focus is on structural upgrading and higher standards, not short-term stimulus. Prioritized Sectors: Policy is heavily concentrated on industries that enhance long-term re...

The Core Conflict: In APAC, culture remains the superpower. AI can process data, but it cannot read a room, navigate hierarchy, or sense unspoken political tension. Key Takeaway: "AI informs speed. Human judgment protects authority and sensibility." Why It Matters: Global playbooks fail when they ignore local context In healthcare, "how/why" matters as much as "what"—...

In our last podcast, we touched on topics around: 1. policy breakthroughs and current regulatory barriers in pilot zones across China, 2. applying real-world data to streamline the review of imported medical products, 3. the lingering challenges for patients to access innovative healthcare products that have already launched overseas 4. some suggestions for future policy breakthroughs.       In th...

In this podcast, we will mostly dive into some of the latest but also long-standing industry and regulatory issues in China surrounding the accessibility of innovative healthcare products, their current policy regulation standings, and what are areas where the industry can call for additional improvement actions.   These actions will not only benefit multinational and domestic healthcare businesse...